Long
ESPR 1W: cholesterol therapy for patients and investors alike
Esperion Therapeutics (ESPR) has broken its long descending trendline and retested the $2.4–$2.6 support area, forming a solid triple bottom with rising volume. The stock is now holding above key moving averages, signaling accumulation. While above $2.5, the technical setup points to a move toward $6.4, aligning with major resistance and the 200-week MA.
Fundamentally, the company enters one of its strongest phases in years. Following earlier liquidity struggles, Esperion has stabilized its operations and regained investor confidence. The core growth driver is Nexletol (bempedoic acid), a non-statin cholesterol-lowering therapy for patients intolerant to statins. In 2025, combined Nexletol and Nexlizet sales jumped over 45% year-on-year, surpassing $170 million for the first nine months. Recent safety data were positive, leading to new approvals across Europe and Japan - expanding partnerships and licensing revenues. Cash position strengthened via milestone payments from Daiichi Sankyo and Viatris, reducing debt and supporting R&D without new dilution. Challenges remain: profitability is still out of reach, as marketing and development expenses stay high, though liquidity provides breathing room. The broader biotech sector’s rebound amid rate-cut expectations adds tailwind to revenue-backed small caps like Esperion.
Tactically, holding above $2.5 keeps the bullish trajectory intact toward $6.4. A weekly close below $2.3 would negate the setup and re-test lower support, though current accumulation favors the upside.
Esperion helps reduce cholesterol - ironic that its chart still raises investors’ heart rate.
Fundamentally, the company enters one of its strongest phases in years. Following earlier liquidity struggles, Esperion has stabilized its operations and regained investor confidence. The core growth driver is Nexletol (bempedoic acid), a non-statin cholesterol-lowering therapy for patients intolerant to statins. In 2025, combined Nexletol and Nexlizet sales jumped over 45% year-on-year, surpassing $170 million for the first nine months. Recent safety data were positive, leading to new approvals across Europe and Japan - expanding partnerships and licensing revenues. Cash position strengthened via milestone payments from Daiichi Sankyo and Viatris, reducing debt and supporting R&D without new dilution. Challenges remain: profitability is still out of reach, as marketing and development expenses stay high, though liquidity provides breathing room. The broader biotech sector’s rebound amid rate-cut expectations adds tailwind to revenue-backed small caps like Esperion.
Tactically, holding above $2.5 keeps the bullish trajectory intact toward $6.4. A weekly close below $2.3 would negate the setup and re-test lower support, though current accumulation favors the upside.
Esperion helps reduce cholesterol - ironic that its chart still raises investors’ heart rate.
Giao dịch đang hoạt động
#ESPR +70% trade in progress, target 6.4 remains a priority - if desired, part of the position can be fixed 
Наш канал: t.me/totoshkatradingteam
⏺ Брокеры которым доверяю:
FxPro - ib-fxpro.com/?ib=SwHtc7m3
AMarkets - profit-market.info/promo/?g=BZA6ZC
⏺ Брокеры которым доверяю:
FxPro - ib-fxpro.com/?ib=SwHtc7m3
AMarkets - profit-market.info/promo/?g=BZA6ZC
Thông báo miễn trừ trách nhiệm
Thông tin và các ấn phẩm này không nhằm mục đích, và không cấu thành, lời khuyên hoặc khuyến nghị về tài chính, đầu tư, giao dịch hay các loại khác do TradingView cung cấp hoặc xác nhận. Đọc thêm tại Điều khoản Sử dụng.
Наш канал: t.me/totoshkatradingteam
⏺ Брокеры которым доверяю:
FxPro - ib-fxpro.com/?ib=SwHtc7m3
AMarkets - profit-market.info/promo/?g=BZA6ZC
⏺ Брокеры которым доверяю:
FxPro - ib-fxpro.com/?ib=SwHtc7m3
AMarkets - profit-market.info/promo/?g=BZA6ZC
Thông báo miễn trừ trách nhiệm
Thông tin và các ấn phẩm này không nhằm mục đích, và không cấu thành, lời khuyên hoặc khuyến nghị về tài chính, đầu tư, giao dịch hay các loại khác do TradingView cung cấp hoặc xác nhận. Đọc thêm tại Điều khoản Sử dụng.